Type 2 diabetic renal complications and microvascular injury: novel predictors of onset and progression, mechanisms of association with cardiovascular disease and the benefits of fenofibrate.

2 型糖尿病肾脏并发症和微血管损伤：发病和进展的新预测因子、与心血管疾病的关联机制以及非诺贝特的益处。

• 批准号: nhmrc : 1017274
• 负责人: Dr Ru-Dee Ting
• 金额: $ 5.63万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Postgraduate Scholarships
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/type-2-diabetic-benefits-fenofibrate/109844
• 关键词: Type; diabetic; renal; complications; microvascular

We will investigate the mechanisms of diabetic complications related to kidney and blood vessel disease, focusing on identifying people at greater risk and ways to improve or prevent these complications. In addition, we will look at how diabetic kidney disease affects non-kidney related problems like heart disease and examine the benefit of fenofibrate on both. This greater understanding will aid further drug development in kidney and cardiovascular diseases.

我们将研究与肾脏和血管疾病相关的糖尿病并发症的机制，重点是识别风险更大的人群以及改善或预防这些并发症的方法。此外，我们将研究糖尿病肾病如何影响心脏病等非肾脏相关问题，并检查非诺贝特对两者的益处。这种更深入的了解将有助于肾脏和心血管疾病的进一步药物开发。